• Kindbody, a fertility services provider, has announced the acquisition of Phosphorus Labs, a preventative genomics company, for an undisclosed sum.

• Founded in 2016, Phosphorus Labs has built a verticalized genetic testing platform that provides clinical-grade genetic testing for genomic information access.

• The acquisition will enable Kindbody to incorporate genomics into patient care. Phosphorus Labs’ 8,000 sq ft lab in New Jersey will bring down Kindbody's existing genetic testing and screening in-house for patient care later this year. Phosphorus Labs’ team of geneticists and lab technicians will also join Kindbody’s new division, KindLabs.

• Before the acquisition, Kindbody outsourced preimplantation genetic testing for aneuploidy (PGT-A) to screen embryos for missing or extra chromosomes during the IVF process and expanded carrier screening (ECS) for genes that can cause disorders.

<ul><li> Analyst QuickTake: The expansion through Phosphorus Labs acquisition aligns with one of the planned uses of Kindbody's USD 62 million Series C fundraise in June 2021. It intended to use the funds to accelerate growth and expand access to its partner, signature, and mobile clinics. The acquisition also marks the company’s second deal in 2022, three months after its acquisition of Vios Fertility Institute and its chain of clinics. During the same period, it also launched its first consumer product , Kind at Home, and forayed into the fertility test kit market for both women and men.</ul>